U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.The Dow traded up 0.18% to 44,319.31 while the NASDAQ gained 0.62% to 20,545.29. The S&P 500 also rose, gaining, 0.31% to 6,245.11.Check This Out: Top 2 Tech Stocks That May Plunge This MonthLeading and Lagging SectorsCommunication services shares jumped by 1.1% on Wednesday.In trading on Wednesday, consumer staples stocks dipped by 1%.Top HeadlineU.S. crude oil inventories increased by 7.07 ...

Extends patent exclusivity period an additional 6 years once grantedSOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application covering the use of GIMOTI® in patients with ...

Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. “We’re pleased to report continued stro ...

SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced that a new abstract comparing the incidence of tardive dyskinesia (TD) in patients receiving continuous versus intermittent oral metoclopramide (OMCP) treatment has been accepted for presentation at Digestive Disease Week® (DDW) 2025, taking place May 3–6, 2025, in San Diego, CA. T ...

Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Company Participants Daniel Kontoh-Boateng ??? DKB Partners Matt D???Onofrio ??? Chief Executive Officer Chris Quesenberry ??? Chief Commercial Officer, GIMOTI, EVERSANA Mark Kowieski ??? Chief Financial Officer Conference Call Participants Yale Jen ??? Laidlaw & Company Operator Good afternoon, and welcome to the Evoke Pharma, Inc. Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently, all callers ha ...